AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Real-time Estimate Cboe Europe 10:18:05 2024-03-28 am EDT 5-day change 1st Jan Change
10,685 GBX -0.53% Intraday chart for AstraZeneca PLC +2.63% +0.96%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
ASTRAZENECA : Deutsche Bank reiterates its Sell rating ZD
AstraZeneca CEO Sees No Impact from Biosecure Act MT
AstraZeneca's RSV Disease Drug, Breast Cancer Combination Therapy Receive Approval in Japan MT
FTSE 100 underperforms ahead of US PCE data AN
C4X Discovery seeks AIM delisting but half-year revenue skyrockets AN
The FTSE 100 stays in the red Our Logo
AstraZeneca: Truqap approved for breast cancer in Japan CF
AstraZeneca treatments become "first and only" to be approved in Japan AN
FTSE 100 slips as unease lingers before US data AN
AstraZeneca: Beyfortus approved in Japan CF
AstraZeneca CEO Soriot on Pharmaceuticals in China MT
Diploma makes buy; Astra wins Japan drug approvals AN
AstraZeneca Wins Japanese Approval for Breast Cancer Treatment MT
AstraZeneca, Sanofi's RSV Prevention Drug Wins Japanese Approval MT
KeyMed Biosciences’ Attributable Loss Widens in 2023 MT
China to speed up 'new productive forces', vice president says RE
AstraZeneca, Pfizer Pledge Support for Expansion of China's Biopharmaceutical Industry MT
Boston Properties Closes Sale of 45% Stake in Life Sciences Property in Massachusetts MT
London Stocks Retreat Ahead of Final UK GDP Data for Q4 2023 MT
Global markets live: United Airlines, Qualcomm, Amazon, Nissan, Boeing... Our Logo
ASTRAZENECA : Gets a Sell rating from UBS ZD
German industry sceptical of China's vow to treat foreign firms equally RE
AstraZeneca Says Ultomiris Gets US FDA Approval to Treat Neuromyelitis Optica Spectrum Disorder MT
Stocks make tepid start to new week AN
The FTSE 100 takes a breather Our Logo
Chart AstraZeneca PLC
More charts
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
135.6 USD
Average target price
161.5 USD
Spread / Average Target
+19.04%
Consensus
  1. Stock
  2. Equities
  3. Stock AstraZeneca PLC - London S.E.
  4. News AstraZeneca PLC
  5. AstraZeneca : Thai Partner Misses COVID-19 Vaccine Delivery Targets